PTIXW VS NEPT Stock Comparison

Performance

PTIXW
10/100

PTIXW returned -30.00% in the last 12 months. Based on SPY's performance of -13.78%, its performance is below average giving it a score of 10 of 100.

NEPT
10/100

NEPT returned -98.27% in the last 12 months. Based on SPY's performance of -13.45%, its performance is below average giving it a score of 10 of 100.

Profit

PTIXW
10/100

Out of the last 20 quarters, PTIXW has had 0 profitable quarters and has increased their profits year over year on 0 of them.

NEPT
13/100

Out of the last 20 quarters, NEPT has had 2 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

PTIXW
67/100

PTIXW has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

NEPT
34/100

NEPT has had a lower than average amount of volatility over the last 12 months giving it a score of 34 of 100.

Analyst Price Targets

PTIXW

"Analyst Price Targets" not found for PTIXW

NEPT
75/100

1 analysts offer 12-month price targets for NEPT. Together, they have an average target of 0, the most optimistic target put NEPT at 0 within 12-months and the most pessimistic has NEPT at 0.

Technicals

PTIXW

"Technicals" not found for PTIXW

NEPT
25/100

NEPT receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

Earnings

PTIXW

"Earnings" not found for PTIXW

NEPT
10/100

NEPT has missed earnings 10 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

Protagenic Therapeutics, Inc. Warrant Summary

Nasdaq / PTIXW

Healthcare

Biotechnology

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Neptune Wellness Solutions Inc. Ordinary Shares Summary

Nasdaq / NEPT

Healthcare

Drug Manufacturers—Specialty & Generic

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company in Canada, the United States, and internationally. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, MaxSimil, and NurturMe brands. The company also offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, including nutraceuticals, beauty and personal care products, and organic foods and beverages. In addition, it is involved in the extraction, purification, formulation, and manufacturing of health and wellness products. Further, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

Power up your portfolio